BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 29
• 30

• 

  How Blockchain Might be Used by Biopharma to Trade Data

  Blockchain is best known—if it’s known at all—as being linked to the cryptocurrency Bitcoin. For those a bit more in the know, it is the underlying data infrastructure that allows Bitcoin to work.In the life sciences, it’s raising the possibility of cross-organizational collaborations.

  April 6, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Unity Biotechnology Looking to Infuse New Life through $85M IPO

  A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.

  April 6, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Incyte Nosedives: Drug Combo Fails Melanoma Phase III Trial

  Shares of Incyte Corporation are down more than 20 percent this morning after the company revealed that pairing is IDO1 drug in combination with Merck’s Keytruda failed to meet endpoints in a Phase III melanoma trial.

  April 6, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Reports: Takeda CEO Discusses Potential Shire Deal in Closed-Door Meeting With Analysts

  Shares of Shire Plc spiked overnight after increased rumors that Japanese pharma giant Takeda could be closer to making a deal to acquire the rare disease company.

  April 6, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Sarepta’s Lawsuit Relief: Other Biotech Targets

  Sarepta Therapeutics is breathing a little easier this morning. On Wednesday a federal appeals court supported a previous court’s decision to dismiss charges that the company misled shareholders as it vied to gain approval for its Duchenne muscular dystrophy treatment.

  April 6, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Evaluating Risk: Gilead Sciences, Biogen and Celgene

  When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.

  April 6, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Novo Nordisk Ties Up Sickle Cell Disease Treatment in $400M Deal

  Danish pharma giant Novo Nordisk tied up a sickle cell and beta-thalassemia program in a $400 million deal with Ohio-based EpiDestiny.

  April 6, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  UPDATED: FDA Issues CLRs for Two Celltrion and Teva Biosimilars

  The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.

  April 6, 2018

   · 

  3 min read

   · 

  Mark Terry
• Biotech Beach

  Club Pilates to Offer Continuing Education Opportunities to Aspiring Pilates Instructors with $70,000+ in Scholarship Giveaways

  Club Pilates is continuing its advocacy for fitness education by awarding more than $70,000 in scholarships for its Teacher Training program in 2018.

  April 6, 2018

   · 

  3 min read
• Business

  Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors

  Magenta Therapeutics announced the addition of Amy Ronneberg to its Board of Directors.

  April 6, 2018

   · 

  3 min read